Today, we’d like to introduce DermaGlue, a leader in next-generation bio-adhesive technology.
DermaGlue is redefining the paradigm of wound care and has recently received official recognition for its advanced and differentiated technology both in Korea and internationally. With major global certifications such as the U.S. FDA and European CE (MDR), DermaGlue is quickly gaining attention in the global medical market.
1. Surpassing Global Standards: Achieving “Triple Certification”
DermaGlue has successfully obtained certifications across the United States, Europe, and Korea, establishing itself as a product that meets global standards worldwide.
• U.S. FDA Certification (CFG)
DermaGlue has been certified for legal distribution and sale within the United States. By meeting the FDA’s strict safety requirements, the product has secured entry into one of the world’s largest medical markets.
• European CE MDR Compliance
Rather than simply maintaining legacy CE certification, DermaGlue complies with the latest EU Medical Device Regulation (MDR 2017/745). This confirms that the product meets the most up-to-date safety and regulatory standards across Europe.
• Korean MFDS Certification
Approved by Korea’s Ministry of Food and Drug Safety, DermaGlue has demonstrated quality and reliability recognized both domestically and internationally.
2. Patented Core Technology: Plant-Based Polymer Innovation
Through continuous research and development, DermaGlue has secured proprietary technology supported by patents.
• Microfibril Polymer Engineering
By utilizing microfibers extracted from plant cell walls, DermaGlue achieves strong adhesion while remaining safe for both humans and animals.
• Balanced Breathability and Waterproofing
The adhesive creates a protective barrier that blocks external contaminants while allowing airflow, helping to accelerate the healing process.
• Flexible and Comfortable Application
Its thin, flexible structure adheres comfortably even to joints and curved areas, eliminating the discomfort commonly associated with traditional bandages.
3. From Veterinary Use to Human Healthcare
DermaGlue initially gained traction in the veterinary bio-adhesive field, establishing strong technological leadership.
Building on that success, the company is now expanding into broader healthcare applications, including:
• medical adhesives
• wound closure solutions
• hemostatic products
• adhesive medical tapes
In a global market projected to grow at double-digit rates annually, DermaGlue is introducing a new approach to wound care:
From stitching wounds → to applying adhesive-based closure
This approach improves efficiency in clinical settings while significantly reducing scarring and pain for patients.
DermaGlue is also being used in TNR (Trap–Neuter–Return) programs for stray animals, demonstrating its versatility and real-world impact.
Innovation in Pet Care
DermaGlue provides advanced wound care solutions for animals, including:
• infection prevention without the need for protective collars
• improved comfort and recovery outcomes
These innovations contribute to a better quality of life for both pets and their owners.
Expanding Global Presence
DermaGlue is actively expanding its global network, partnering with medical distributors in countries such as:
• Brazil
• Uzbekistan
• Vietnam
Through these partnerships, the company continues to strengthen the global presence of Korean biotechnology.
4. A New Standard in Wound Care
DermaGlue is not simply designed to cover wounds. It is built to provide a safer and more efficient method of healing.
The recent FDA and CE MDR certifications mark a significant milestone in the company’s journey toward setting a new standard in wound management.
Key Achievements
• FDA CFG Certification (United States)
• CE MDR Declaration of Conformity (Europe)
• Proprietary patented technology
• Accelerating global distribution partnerships